-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Coronavirus disease 2019 (Covid-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-cov-2).
The new crown pneumonia recently, researchers examined in the home environment, REGEN-COV preventive treatment on close contacts of patients newly diagnosed with pneumonia crown of the follow-up of risk
Participants in this study are close contacts of family members within 96 hours after the diagnosis of infection , who are over 12 years old, and randomly receive a total dose of 1200 mg of REGEN-CoV or placebo by subcutaneous injection
Infect
11 of the 753 participants in the REGEN-CoV group (1.
11 of the 753 participants in the REGEN-CoV group (1.
REGEN-COV significantly reduces the risk of subsequent illnesses in close contacts
REGEN-COV significantly reduces the risk of subsequent illness in close contacts REGEN-COV greatly reduces the risk of subsequent illness in close contactsStudies believe that in close family contacts of patients with new coronary pneumonia, subcutaneous injection of REGEN-COV can effectively reduce the risk of infection.
Among the close family contacts of patients with new coronary pneumonia, subcutaneous injection of REGEN-COV can effectively reduce the risk of infection.
Original source:
Meagan P.
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
Leave a message here
